statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx senior management team will host a conference...

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol...

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class...

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Amylyx...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the...

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders Levi & Korsinsky Announces the Filing of a Securities Class Action on...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX Amylyx Pharmaceuticals, Inc. Sued for Securities Law...

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX

AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire...

AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced the Company has started a process with the U.S. Food and Drug Administration (FDA) and Health Canada to voluntarily...

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

AMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities...

AMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Volume	1.48M
52-Wk High	$30.50
52-Wk Low	$1.70

AMLX Amylyx Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals